Pharmacodynamic Biomarkers to Support Biosimilar Development: Clinical Study 3 - Interferon Beta-1A and Peginterferon Beta-1A
Phase: PHASE1
Conditions: Healthy Subjects, Pharmacokinetics, Pharmacodynamics
Sponsor: Food and Drug Administration (FDA)

Study Title: Pharmacodynamic Biomarkers to Support Biosimilar Development: 
Clinical Study 3 (IFN-β Products – Avonex and Plegridy) 
 
Document Title: Clinical Study Protocol – Study No. SCR-008 
 
Document Date : 17 August 2020 
 
NCT Number: NCT04183491